We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Geron (GERN) Dips More Than Broader Markets: What You Should Know
Read MoreHide Full Article
Geron (GERN - Free Report) closed the most recent trading day at $2.30, moving -1.71% from the previous trading session. This change lagged the S&P 500's 1.65% loss on the day. At the same time, the Dow lost 1.63%, and the tech-heavy Nasdaq lost 6.65%.
Heading into today, shares of the drugmaker had lost 15.22% over the past month, lagging the Medical sector's loss of 1.27% and the S&P 500's gain of 0.3% in that time.
Investors will be hoping for strength from Geron as it approaches its next earnings release. In that report, analysts expect Geron to post earnings of -$0.09 per share. This would mark no growth from the year-ago period. Our most recent consensus estimate is calling for quarterly revenue of $0.14 million, up 16.67% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$0.39 per share and revenue of $0.6 million. These totals would mark changes of -5.41% and +0.67%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for Geron. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 9.15% lower within the past month. Geron is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 95, putting it in the top 38% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Geron (GERN) Dips More Than Broader Markets: What You Should Know
Geron (GERN - Free Report) closed the most recent trading day at $2.30, moving -1.71% from the previous trading session. This change lagged the S&P 500's 1.65% loss on the day. At the same time, the Dow lost 1.63%, and the tech-heavy Nasdaq lost 6.65%.
Heading into today, shares of the drugmaker had lost 15.22% over the past month, lagging the Medical sector's loss of 1.27% and the S&P 500's gain of 0.3% in that time.
Investors will be hoping for strength from Geron as it approaches its next earnings release. In that report, analysts expect Geron to post earnings of -$0.09 per share. This would mark no growth from the year-ago period. Our most recent consensus estimate is calling for quarterly revenue of $0.14 million, up 16.67% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$0.39 per share and revenue of $0.6 million. These totals would mark changes of -5.41% and +0.67%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for Geron. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 9.15% lower within the past month. Geron is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 95, putting it in the top 38% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.